| Assessment Status | Rapid Review Complete |
| HTA ID | 25003 |
| Drug | Nivolumab with Ipilimumab |
| Brand | Opdivo® with Yervoy® |
| Indication | Nivolumab (Opdivo®) with Ipilimumab (Yervoy®) is indicated for the first-line treatment of adult patients with unresectable or metastatic mismatch repair deficient or microsatellite instability-high colorectal cancer. |
| Assessment Process | |
| Rapid review commissioned | 08/01/2025 |
| Rapid review completed | 14/02/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Nivo+Ipi not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. October 2025